Patents by Inventor David Binninger

David Binninger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8765808
    Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: July 1, 2014
    Assignee: CHS Pharma, Inc.
    Inventors: Herbert Weissbach, Lionel Resnick, David Binninger
  • Patent number: 8603985
    Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: December 10, 2013
    Assignee: CHS Pharma, Inc
    Inventors: Herbert Weissbach, Lionel Resnick, David Binninger
  • Patent number: 8357720
    Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with an agent that generates or induces reactive oxygen species (ROS), significantly enhances the killing of abnormal cells but does not affect normal cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against the abnormal cells.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: January 22, 2013
    Assignee: Florida Atlantic University
    Inventors: Herbert Weissbach, Lionel Resnick, David Binninger
  • Patent number: 8258181
    Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.
    Type: Grant
    Filed: March 23, 2006
    Date of Patent: September 4, 2012
    Assignee: Florida Atlantic University
    Inventors: Herbert Weissbach, Lionel Resnick, David Binninger
  • Publication number: 20100260864
    Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.
    Type: Application
    Filed: April 14, 2010
    Publication date: October 14, 2010
    Applicant: Florida Atlantic University
    Inventors: Herbert Weissbach, Lionel Resnick, David Binninger
  • Publication number: 20100069331
    Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with an agent that generates or induces reactive oxygen species (ROS), significantly enhances the killing of abnormal cells but does not affect normal cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against the abnormal cells.
    Type: Application
    Filed: September 10, 2009
    Publication date: March 18, 2010
    Applicant: Florida Atlantic University
    Inventors: Herbert Weissbach, Lionel Resnick, David Binninger
  • Publication number: 20080119559
    Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.
    Type: Application
    Filed: October 26, 2007
    Publication date: May 22, 2008
    Applicant: Florida Atlantic University
    Inventors: HERBERT WEISSBACH, Lionel Resnick, David Binninger
  • Publication number: 20060235080
    Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.
    Type: Application
    Filed: March 23, 2006
    Publication date: October 19, 2006
    Applicant: Florida Atlantic University
    Inventors: Herbert Weissbach, Lionel Resnick, David Binninger